GLSI
Greenwich LifeSciences, Inc.
Pharmaceutical PreparationsNasdaq<br>Emerging growth company
Total Trades
89
Buys
89
Sells
0
Largest Trade
$1M+
Insiders
4
Institutional Funds
37
Inst. Value
$1M+
Activist Filings
1
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 2K | $29.83 | Jan 15, 2026 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 3K | $27.54 | Jan 14, 2026 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 4K | $21.36 | Jan 5, 2026 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 3K | $21.73 | Jan 2, 2026 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 4K | $12.62 | Dec 19, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 5K | $8.37 | Nov 28, 2025 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 11K | $8.43 | Nov 12, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $9.26 | Nov 4, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 4K | $9.88 | Apr 29, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 5K | $8.98 | Apr 22, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 4K | $9.10 | Apr 8, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 6K | $8.73 | Apr 7, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $12.51 | Jan 13, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $13.58 | Jan 8, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $12.95 | Jan 7, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $11.97 | Jan 6, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $11.36 | Jan 3, 2025 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $11.12 | Jan 2, 2025 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 1K | $12.91 | Nov 25, 2024 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $14.63 | Sep 30, 2024 |
| Patel Snehal | CEO and CFO | BUY | $1M+ | 175K | $14.30 | Jun 17, 2024 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 3K | $19.08 | Apr 3, 2024 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $19.98 | Mar 26, 2024 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $17.68 | Mar 22, 2024 |
| Patel Snehal | CEO and CFO | BUY | $100K–$500K | 11K | $11.16 | Feb 21, 2024 |
| Patel Snehal | CEO and CFO | BUY | $100K–$500K | 13K | $11.07 | Feb 20, 2024 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 5K | $10.17 | Nov 14, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 4K | $9.11 | Nov 7, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 500 | $8.57 | Oct 31, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $7.97 | Oct 30, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $7.91 | Oct 27, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.07 | Oct 12, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $8.63 | Oct 5, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 600 | $8.71 | Sep 28, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 4K | $8.95 | Sep 21, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.48 | Sep 13, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.97 | Aug 24, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $10.55 | Aug 8, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.20 | Jul 25, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $9.49 | Jul 17, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $11.69 | May 18, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $11.22 | May 2, 2023 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 7K | $11.10 | Apr 21, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $11.12 | Apr 20, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 1K | $11.87 | Apr 12, 2023 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 5K | $12.42 | Apr 12, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $12.71 | Mar 16, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $12.12 | Mar 13, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $15.39 | Feb 28, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 600 | $16.53 | Feb 22, 2023 |
🔓Seeing ranges? Sign in for exact trade values — free forever
Institutional Ownership
13F filings as of Dec 31, 2025 · 37 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 132K | $1M+ | SH |
| STATE STREET CORP | 98K | $1M+ | SH |
| VANGUARD GROUP INC | 45K | $500K+ | SH |
| Virtu Financial LLC | 29K | $500K+ | SH |
| Man Group plc | 28K | $500K+ | SH |
| GOLDMAN SACHS GROUP INC | 22K | $100K–$500K | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19K | $100K–$500K | SH |
| MORGAN STANLEY | 10K | $100K–$500K | SH |
| BARCLAYS PLC | 10K | $100K–$500K | SH |
| RHUMBLINE ADVISERS | 8K | $100K–$500K | SH |
| NEW YORK STATE COMMON RETIREMENT FUND | 6K | $100K–$500K | SH |
| STRS OHIO | 6K | $100K–$500K | SH |
| Bank of New York Mellon Corp | 5K | $100K–$500K | SH |
| Police & Firemen's Retirement System of New Jersey | 3K | $50K–$100K | SH |
| BlackRock, Inc. | 3K | $50K–$100K | SH |
| Newbridge Financial Services Group, Inc. | 2K | $15K–$50K | SH |
| BNP PARIBAS FINANCIAL MARKETS | 2K | $15K–$50K | SH |
| UBS Group AG | 1K | $15K–$50K | SH |
| DEUTSCHE BANK AG\ | 1K | $15K–$50K | SH |
| WELLS FARGO & COMPANY/MN | 1K | $15K–$50K | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G · Jun 22, 2022
17.7%
2.3M shares